13F Portfolios

Fairmount Funds Management LLC: JADE BIOSCIENCES INC (JBIO): Quarterly 13F Position History

As of Q1 2026, Fairmount Funds Management LLC reported 4,553,494 shares of JADE BIOSCIENCES INC (JBIO), worth $64.0M and representing 4.6% of its 13F equity book. The position first appeared in Q2 2025 and has been disclosed across 4 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 4 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 4,553,494 0 $64.0M 4.6% $14.1
Q4 2025 4,553,494 +1,333,126 +41.4% $70.3M 5.3% $15.4
Q3 2025 3,220,368 0 $27.8M 2.5% $8.6
Q2 2025 3,220,368 $32.2M 4.2% $10.0

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Fairmount Funds Management LLC first disclose a JBIO position in 13F-HR filings?

Fairmount Funds Management LLC first reported JADE BIOSCIENCES INC (JBIO) on its 13F-HR filing for the period ending 2025-06-30 (Q2 2025). The position has appeared on 4 reported quarters within Pactolio's tracked window.

What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in JBIO?

Fairmount Funds Management LLC held the same 4,553,494 shares of JBIO between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in JBIO?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.